论文部分内容阅读
目的探讨左氧氟沙星联合奥硝唑及埃索美拉唑治疗慢性胃炎患者的临床疗效。方法选取2013年7月至2015年1月广州市越秀区黄花岗街社区卫生服务中心收治的88例慢性胃炎患者作为研究对象,按接受治疗先后顺序随机将其分为A组与B组,各44例。A组患者给予阿莫西林、克拉霉素和埃索美拉唑,B组患者采用左氧氟沙星、奥硝唑及埃索美拉唑进行治疗,比较两组患者的临床疗效、幽门螺杆菌(Hp)清除率、并发症发生情况、3个月复发率及症状缓解时间。结果 B组患者治疗的总有效率明显高于A组,差异有统计学意义(P<0.05);B组患者治疗1个月后幽门螺杆菌清除率明显高于A组,并发症发生率和3个月复发率均明显低于A组,差异均有统计学意义(均P<0.05);B组患者饱胀、疼痛、恶心反酸症状缓解时间均明显短于A组,差异均有统计学意义(均P<0.05)。结论左氧氟沙星联合奥硝唑及埃索美拉唑治疗慢性胃炎患者临床效果确切,可有效提高幽门螺杆菌清除率,促进症状缓解,降低复发率,安全性高。
Objective To investigate the clinical efficacy of levofloxacin combined with ornidazole and esomeprazole in the treatment of patients with chronic gastritis. Methods A total of 88 chronic gastritis patients admitted to Huanghuagang Street Community Health Service Center in Yuexiu District of Guangzhou City from July 2013 to January 2015 were selected and divided into A group and B group according to the order of their receiving treatment 44 cases. Patients in group A were given amoxicillin, clarithromycin, and esomeprazole. Patients in group B were treated with levofloxacin, ornidazole and esomeprazole. The clinical efficacy, Hp (Helicobacter pylori) Clearance rate, the incidence of complications, 3-month recurrence rate and symptom relief time. Results The total effective rate of treatment in group B was significantly higher than that in group A (P <0.05). The clearance rate of Helicobacter pylori in group B was significantly higher than that in group A after one month of treatment, and the complication rate and 3 months recurrence rate were significantly lower than the A group, the differences were statistically significant (all P <0.05); B group of patients with fullness, pain, nausea and acid reflux symptoms were significantly shorter than the A group, the difference was statistically Significance (both P <0.05). Conclusion Levofloxacin combined with ornidazole and esomeprazole treatment of patients with chronic gastritis clinical effect is exact, can effectively improve the clearance rate of Helicobacter pylori, promote symptom relief, reduce the recurrence rate, high safety.